Evaluation of lipoprotein(a) — a novel cardiovascular risk factor in patients with atherosclerotic cardiovascular diseases receiving PCSK9-targeted therapy in Russian real-world practice

A. I. Sapina; Yu. Yu. Varlamova; M. G. Papyrina; A. S. Bezymyannyy; E. L. Kordzaya; E. Yu. Vasilyeva

Russian Journal of Cardiology

ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)

User

eng | рус

Russian Journal of Cardiology

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Sapina A.I., Varlamova Yu.Yu., Papyrina M.G., Bezymyannyy A.S., Kordzaya E.L., Vasilyeva E.Yu. Evaluation of lipoprotein(a) — a novel cardiovascular risk factor in patients with atherosclerotic cardiovascular diseases receiving PCSK9-targeted therapy in Russian real-world practice. Russian Journal of Cardiology. 2024;29(12):6177. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6177. EDN: ASISCG

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)

* not an advertisement

About the Authors

A. I. Sapina
I.V. Davydovsky City Clinical Hospital; Research Institute for Healthcare and Medical Management of the Department of Health of the city of Moscow
Russian Federation

Moscow

Yu. Yu. Varlamova
Diagnostic and Clinical Center № 1
Russian Federation

Moscow

M. G. Papyrina
City Clinic № 46
Russian Federation

Moscow

A. S. Bezymyannyy
Directorate for coordination of activities of medical organizations of the Department of Health of the city of Moscow
Russian Federation

Moscow

E. L. Kordzaya
I.V. Davydovsky City Clinical Hospital
Russian Federation

Moscow

E. Yu. Vasilyeva
I.V. Davydovsky City Clinical Hospital; Russian University of Medicine
Russian Federation

Moscow

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Russian Journal of Cardiology

For citations:

Cookies policy